Dapagliflozin Significantly Reduces Plasma Glucose in PIII Study in Japan, Findings Reported at ADA

Dapagliflozin, a sodium glucose co-transporter-2 (SGLT-2) inhibitor, significantly reduced plasma glucose and body weight in Japanese diabetes patients compared to placebo in a PIII study, Kawasaki Medical School Professor Kohei Kaku reported at the American Diabetes Association (ADA) held in...read more